Thromb Haemost 1963; 10(01): 106-119
DOI: 10.1055/s-0038-1660337
Originalarbeiten — Original Article — Travaux Originaux
Schattauer GmbH

Inhibition of Fibrinolysis and Fibrinogenolysis in Man: Comparison of ε-Aminocaproic Acid and Kallikrein Inhibitor

E Beck*
1   Blood Coagulation Laboratory (Head: Dr. F. Duckert) of the First Medical Department (Head:.Prof. F. Koller), Bürgerspital, University of Basel, Switzerland
,
R Schmutzler
1   Blood Coagulation Laboratory (Head: Dr. F. Duckert) of the First Medical Department (Head:.Prof. F. Koller), Bürgerspital, University of Basel, Switzerland
,
F Duckert
1   Blood Coagulation Laboratory (Head: Dr. F. Duckert) of the First Medical Department (Head:.Prof. F. Koller), Bürgerspital, University of Basel, Switzerland
,
Technical assistance: L. Müller and C. Vogel› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. Juli 2018 (online)

Preview

Summary

Inhibitor of kallikrein and trypsin (KI) extracted from bovine parotis was compared with ε-aminocaproic acid (EACA): both substances inhibit fibrinolysis induced with streptokinase. EACA is a strong inhibitor of fibrinolysis in concentrations higher than 0, 1 mg per ml plasma. The same amount and higher concentrations are not able to inhibit completely the proteolytic-side reactions of fibrinolysis (fibrinogenolysis, diminution of factor V, rise of fibrin-polymerization-inhibitors). KI inhibits well proteolysis of plasma components in concentrations higher than 2,5 units per ml plasma. Much higher amounts of KI are needed to inhibit fibrinolysis as demonstrated by our in vivo and in vitro tests.

Combination of the two substances for clinical use is suggested. Therapeutic possibilities are discussed.

* Present address: Division of Hematology, the Johns Hopkins Hospital, Baltimore, Maryland, U.S.A.